Drug intelligence / Profile preview

B867-ADC

Development stage: Preclinical
Lead developer: 山西纳安生物科技
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

B867-ADC is a preclinical-stage bispecific antibody-drug conjugate (ADC) developed by Shanxi Naan Biotechnology for the treatment of malignant solid tumors. As a bispecific ADC, it is designed to simultaneously target two distinct tumor-associated antigens or epitopes, which may enhance tumor selectivity and facilitate the internalization of its cytotoxic payload. The drug is intended for intravenous administration and is currently in the early stages of development.

Other names: B867-ADCB-867-ADCB 867-ADC

Beyond the preview

Go deeper on B867-ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B867-ADC.

Explore the full profile